Gilead Sciences to Release Third Quarter 2002 Financial Results On Thursday, October 31, 2002; Conference Call and Webcast to Follow

FOSTER CITY, Calif., Oct 28, 2002 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its third quarter 2002 financial results will be released on Thursday, October 31, 2002, at 4:00 p.m. Eastern Time. At 4:30 p.m. Gilead will webcast a conference call live on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer, Mark Perry, Executive Vice President of Operations, and John Milligan, PhD, Senior Vice President and Chief Financial Officer.

To access the live call or the seven-day archive via the internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to view the webcast. Alternatively, please call 800/946-0712 (U.S.) or 719/457-2641 (international) to access the call. Telephone replay is available approximately two hours after the call through 8:30 p.m. EST, November 7, 2002. To access, please call 888/203-1112 (U.S.) or 719/457-0820 (international). The conference ID number is 396392.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Gilead Sciences

CONTACT:          Gilead Sciences
                  Susan Hubbard, 650/522-5715 (Investor Relations)

(c) 2002 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.